Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Phase III study in HER2-positive advanced breast cancer shows overall survival benefit when Tykerb is combined with paclitaxel
Phase III study, women with untreated HER2+ metastatic breast cancer improved when treated with a combination of lapatinib & paclitaxel
-
Data from Tykerb investigational phase III studies in neo-adjuvant HER2-positive breast cancer presented at breast cancer symposium
Results from 2 Phase III studies examining Tykerb with trastuzumab in the neo-adjuvant setting of HER2+ breast cancer with chemotherapy
-
GSK signs agreement to acquire Nanjing MeiRui Pharmaceuticals in China
GSK in agreement to acquire MeiRui for approx $70 million. 90% of share capital is to be acquired from Pagoda, remaining 10 from Allergon.
-
GlaxoSmithKline and Human Genome Sciences announce FDA extension of Benlysta® PDUFA target date to 10th March 2011
GSK & HGS announced, FDA has extended the PDUFA target date for its priority review of BLA for Benlysta as a potential treatment for SLE.
-
Avodart reviewed by FDA advisory committee for prostate cancer risk reduction
GSK announced, results of FDA ODAC meeting to discuss sNDA for Avodart, reducing the risk of prostate cancer in men at risk of the disease
-
GSK and Valeant announce receipt of U.S. FDA Complete Response letter for ezogabine
GSK & VRX announced receipt of CRL from FDA for NDA for ezogabine*, a drug studied for the treatment of adults with partial-onset seizures.
-
Government patent box proposals ‘transform’ UK attractiveness for investment
GSK welcomes Gov proposals to establish a patent box, designed to encourage investment in R&D, by introducing a lower corporation tax.
-
GlaxoSmithKline to increase its shareholding in Theravance
GSK to increase shareholding in THRX through stock purchase of 5,750,000 shares for $22.50 per share, a total investment of $129,375,000.
-
GlaxoSmithKline and JSC Binnopharm enter vaccine production alliance in Russia
GSK and JSC Binnopharm today announced an alliance to enable the local secondary manufacture of a number of GSK vaccines in Russia.
-
Human Genome Sciences and GlaxoSmithKline announce vote of FDA advisory committee to recommend approval of Benlysta® for systemic lupus erythematosus
GSK & HGS announced, FDA has voted 13 to 2 to recommend BENLYSTA for the treatment of autoantibody-positive patients with active SLE.
-
New study findings show no benefit of prescription omega-3 fatty acids in prevention of recurrent symptomatic atrial fibrillation in affected patients
Findings from study show treatment with high-dose prescription omega-3 fatty acids did not reduce the recurrence of symptomatic AF.
-
GlaxoSmithKline and Fiocruz extend innovative collaboration to research and develop new medicines for neglected tropical diseases
GSK and Fiocruz have today announced a unique collaboration to research and develop new and innovative medicines to treat diseases.
-
GlaxoSmithKline receives approval in Japan for two medicines: Revolade and Xyzal
GSK announced that it has received approval in Japan from the Ministry of Health, Labour and Welfare for Revolade (eltrombopag).
-
GSK and Amicus Therapeutics enter exclusive worldwide agreement to develop and commercialise Amigal™ for Fabry disease
GSK and Amicus today announced a definitive agreement to develop and commercialise AmigalTM (migalastat HCl),
-
GSK completes previously reported settlement with U.S. Department of Justice regarding former manufacturing plant
GSK announced that it has finalised an agreement with the U.S. Attorneys Office for the District of Massachusetts and DOJ.
-
GSK announces Q3 results for 2010
Q3 EPS before major restructuring of 28.2p
-
GSK outlines approach to delivering advances in the treatment of rare diseases
Creating an environment that fosters innovation, intuition and scientific acumen to deliver breakthrough thinking and new medicines
-
GSK, Fondazione Telethon and Fondazione San Raffaele to collaborate on gene therapy for rare diseases
GSK, Fondazione Telethon and Fondazione San Raffaele today announced a new strategic alliance to research and develop novel treatments.
-
GSK increases support for WHO strategy to improve children’s health with new 5-year commitment to expand donations of albendazole medicine
At the launch of the World Health Organizations (WHO) first report on Neglected Tropical Diseases today.
-
GSK takes minority stake in newly formed Convergence Pharmaceuticals
GSK announced that it has taken an 18% minority equity stake in Convergence Pharmaceuticals Limited.
